Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2009
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing virus-like-particle (VLP) vaccines for infectious diseases, including avian influenza (H5N1), seasonal influenza, Varicella Zoster (VZV), and Respiratory Syncytial Virus (RSV). The company operates with an accumulated deficit and relies on financing and collaborations to fund research and development.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenues | $21 | $458 |
| Net Loss | $(8,349) | $(7,755) |
| Net Loss Per Share (Basic & Diluted) | $(0.12) | $(0.13) |
| Operating Expenses | $7,158 | $7,678 |
| Cash and Cash Equivalents (End of Period) | $19,629 | $14,702 |
| Short-term Investments (Fair Value) | $5,958 | $6,962 |
| Total Debt (Convertible Notes + Notes Payable) | $22,853 | $22,808 |
| Working Capital | $(190) | $7,379 |
Note: Working Capital calculated as Total Current Assets ($26,642) minus Total Current Liabilities ($26,832).
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped 95% to $21,000 from $458,000 in Q1 2008, primarily due to the completion of National Institutes of Health (NIH) contracts in the prior year.
- Net Loss Increase: Net loss increased by $594,000 (8%) to $8.3 million. This was driven by a $879,000 impairment charge on short-term investments (auction rate securities) and lower revenue, partially offset by a $520,000 reduction in operating expenses.
- Operating Expenses: Total operating costs decreased 7% to $7.2 million. Research and Development (R&D) expenses fell 4% to $4.3 million due to facility consolidation and lower employee costs. Selling, General, and Administrative (SG&A) expenses fell 11% to $2.9 million.
- Liquidity Position: Cash and cash equivalents decreased by $7.3 million during the quarter due to operating losses and debt principal payments. The company moved from a working capital surplus of $7.4 million in December 2008 to a deficit of $0.2 million in March 2009.
Guidance, Outlook, and Material Events
Subsequent Events and Financing
- Cadila Partnership: On March 31, 2009, Novavax entered into a Joint Venture (JV) with Cadila Pharmaceuticals Ltd. for the Indian market. Cadila agreed to contribute approximately $8 million over three years. Simultaneously, a subsidiary of Cadila agreed to purchase 12.5 million shares of Novavax stock for gross proceeds of $11 million (net ~$10.5 million), closing April 1, 2009.
- At-the-Market Issuance: Novavax sold 70,500 shares in Q1 2009 for net proceeds of $121,457. As of May 5, 2009, an additional 3.1 million shares were sold for approximately $7.5 million.
- Convertible Notes Amendment: On April 29, 2009, Novavax amended $17.0 million of its $22.0 million senior convertible notes (maturing July 15, 2009). The company paid $12.1 million in cash and issued 2.04 million shares to settle this portion. $5.0 million in principal remains outstanding.
Liquidity and Risks
- Cash Runway: Management believes cash on hand, plus proceeds from the Cadila transaction and At-the-Market sales, will fund operations for at least 12 months. However, additional capital raising is planned for 2009.
- Auction Rate Securities: The company holds $6.0 million in fair value of auction rate securities (par value $8.1 million) which are illiquid. An impairment charge of $0.9 million was recorded in Q1 2009.
- Debt Maturity: The remaining $5.0 million in convertible notes matures July 15, 2009. The company may pay up to 50% of this in stock, but must pay at least $2.5 million in cash unless converted or amended.
Investor Verification Checklist
- Debt Settlement: Verify the final cash outflow and share issuance details regarding the April 29, 2009, settlement of the $17 million convertible notes.
- Cadila Transaction Closing: Confirm receipt of the $10.5 million net proceeds from the Cadila stock purchase and the status of the Joint Venture regulatory approvals in India.
- Auction Rate Securities: Assess the current marketability and potential for further impairment on the $6.0 million holding of illiquid auction rate securities.
- Capital Needs: Monitor announcements regarding the company's plan to raise additional capital beyond the 12-month runway to fund R&D and the July 2009 note maturity.
- Related Party Transactions: Review the terms of the Master Services Agreement with Cadila, specifically the $7.5 million service commitment and potential shortfall payments.